Brief: Humanigen Announces Target Enrollment in Phase 2/3 Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

Humanigen

05/01/2022 11:27

Jan 5 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN ANNOUNCES TARGET ENROLLMENT IN PHASE 2/3
ACTIV-5/BET-B
TRIAL OF LENZILUMAB FOR THE TREATMENT OF COVID-19 HAS BEEN
ACHIEVED
    * HUMANIGEN INC - TOP-LINE DATA FROM ACTIV-5/BET-B EXPECTED
TO BE
ANNOUNCED LATE IN Q1 OR EARLY IN Q2 OF 2022

Source text for Eikon:  ID:nBw1K7sysa 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;;))